Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 30;14:848180. doi: 10.3389/fnagi.2022.848180

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Chen, Lin, Huang, Xue and Tao.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Role of each biomarker in cognitive change measured by ADAS13. (A–F) Show the annual ADAS13 change in cognitive impairment population with Aβ-positive. For directly illustration, each plot compares ADAS scores between the subgroup who scored below the median (in red) and the subgroup who scored above the median (in green) on the variable in the plot title. (A) Shows higher CSF p-tau concentration has faster cognitive decline in 8-year follow-up. (B) Illustrates higher CSF soluble TREM2 concentration is associated with slower cognitive change. (C–F) Show larger specific brain region volume (including hippocampal, entorhinal, and middle temporal and whole brain) is associated with slower cognitive decline. Brain volumes are segmented from 3.0 T structural MRI.